• osmi br Prostate cancer and resistance to AR

  2023-01-10

  

  Prostate cancer and resistance to AR targeting treatment The AR plays a pivotal role in the development, differentiation, homeostasis and secretory function of the normal prostate (Wilson, 2011). The AR is also a key player in many phases of prostate carcinogenesis (Huggins et al., 1941, Scher an

• A number of studies suggest that adiponectin promotes osteob

  2023-01-09

  

  A number of studies suggest that adiponectin promotes osteoblast differentiation and bone formation by directly targeting GSK-3β and β-Catenin signaling [64], [65], favoring bone marrow mesenchymal stem cell (BMSC) differentiation toward the osteoblastic lineage [66], [67], decreasing sympathetic to

• Mechanisms implicated in antinociception by A

  2023-01-09

  

  Mechanisms implicated in antinociception by A3R agonists in neuropathic pain are summarized in Box 3. Cellular transduction mechanisms for A3Rs include inhibition of cyclic AMP, PKA via Gαi, interactions with PLC/IP3/DAG and signaling via Gαi and Gαq, and interactions with PI3K/MEK/ERK via βγ subuni

• Several reports of single cases of MG

  2023-01-09

  

  Several reports of single cases of MG patients treated with Rituximab have claimed a favourable response (Baek et al., 2007, Gajra et al., 2004, Hain et al., 2006, Thakre et al., 2007, Wylam et al., 2003, Zaja et al., 2000). We report our experience with Rituximab in 6 patients with severe MG, 3 pa

• In conclusion we have produced some highly

  2023-01-09

  

  In conclusion, we have produced some highly potent inhibitors of P450 in comparison to the standard CA-074 synthesis KTZ. Also, due to the limited specificity of these compounds against lyase in comparison to the 17α-OHase component, these compounds would be expected to have a major impact on cortic

• Steroidal CYP inhibitors can further

  2023-01-09

  

  Steroidal CYP17 inhibitors can further be classified based on their mode of action, namely as mechanism-based inhibitors and type I and type II competitive inhibitors [129]. Recent studies investigated other biological targets than CYP17, and some new compounds have shown interesting dual activity a

• br Declaration of interest br Funding br

  2023-01-09

  

  Declaration of interest Funding Introduction The endocrine disruptor bisphenol A (BPA) is a high-production chemical used in several consumer products, including polycarbonate bottles, epoxy resins, dental sealants, and thermal paper receipts (Geens et al., 2012). Importantly, BPA monomers

• br Angiotensin receptor neprilysin inhibitors Sacubitril val

  2023-01-09

  

  Angiotensin receptor-neprilysin inhibitors Sacubitril/valsartan is the first-in-class ARNI, comprising of molecular moieties of valsartan (ARB) and a neprilysin inhibitor prodrug, sacubitril (AHU377) [51]. Upon ingestion, sacubitril is rapidly metabolised into an active neprilysin inhibitor, sacu

• br Prostate cancer and resistance to AR

  2023-01-09

  

  Prostate cancer and resistance to AR targeting treatment The AR plays a pivotal role in the development, differentiation, homeostasis and secretory function of the normal prostate (Wilson, 2011). The AR is also a key player in many phases of prostate carcinogenesis (Huggins et al., 1941, Scher an

• br A and tau in Alzheimer s

  2023-01-09

  

  Aβ and tau in Alzheimer's disease The two classical histopathological hallmarks of AD are extracellular insoluble Aβ deposits, known as Aβ plaques, and intracellular accumulations of insoluble microtubule-associated tau protein, known as neurofibrillary tangles [14]. Aβ peptides are produced as a

• Lorlatinib is an orally active brain penetrant cyclic aminop

  2023-01-09

  

  Lorlatinib is an orally active brain penetrant cyclic 2-aminopyridine derivative that is a type I½ B ALK inhibitor (Fig. 5F) [61]. This medicinal is an effective antagonist against the more common L1196M and G1269A crizotinib-resistant mutations as well as the less common T1151Ins, L1152R, C1156Y, F

• br Conclusion In summary screening a small compound library

  2023-01-05

  

  Conclusion In summary, screening a small compound library based on the 3-aminopyridin-2-one motif in a target-blind manner against a 26-kinase panel, representative of the kinome, identified hits that possess good activity and excellent ligand efficiency against MPS1, Aurora A and Aurora B. The b

• br Transparency document br Acknowledgments This work has

  2023-01-05

  

  Transparency document Acknowledgments This work has been supported by the National Eye Institute (NIH) Grant 5R01EY023315-02 (MA). This study was also supported in part by National Center for Research Resources Grant S10RR027926 for the lipid analysis and by James and Jean Culver Vision Discov

• Ferulenol synthesis To evaluate the ability of both sets of

  2023-01-05

  

  To evaluate the ability of both sets of compounds to inhibit the activity of 15-LOX an initial screen was performed, whose results are shown in . The comparison of inhibition values would seem to indicate that, in the HYD series, an electron donor group at the position increases and an electron at

• Second the choice of the PAABD

  2023-01-05

  

  Second, the choice of the PAABD is critical for an efficient and sensitive biosensor. The sequence of the PAABD should present high affinity and efficient recognition of the phosphorylated substrate, as opposed to poor affinity for the unphosphorylated substrate, and should display a fully reversibl

15977 records 342/1066 page Previous Next First page 上5页 341342343344345 下5页 Last page